Preclinical Study of Therapeutic Efficacy of a New Russian Radiopharmaceutical 177Lu-DOTA-PSMA

The therapeutic efficacy of a Russian radiopharmaceutical 177 Lu-DOTA-PSMA was studied in vivo using male BALB/c nu/nu (nude) mice with prostate carcinoma 22Rv1 xenografts by tumor growth inhibition criterion. The mean tumor volumes in mice treated with 177 Lu-DOTA-PSMA were significantly lower than...

Full description

Saved in:
Bibliographic Details
Published inBulletin of experimental biology and medicine Vol. 176; no. 2; pp. 224 - 226
Main Authors Tishchenko, V. K., Vlasova, O. P., Lebedeva, A. A., Fedorova, A. V., Pankratov, A. A., Morozova, N. B., Kuzenkova, K. A., Stepchenkova, E. D., Shegai, P. V., Ivanov, S. A., Kaprin, A. D.
Format Journal Article
LanguageEnglish
Published New York Springer US 01.12.2023
Springer Nature B.V
Subjects
Acids
Antigens
Biomedical and Life Sciences
Biomedicine
Cell Biology
Dosimetry
Internal Medicine
Laboratory animals
Laboratory Medicine
Medical research
Metastasis
Pathology
Pharmaceuticals
Prostate cancer
Prostate carcinoma
Radioisotopes
Tumors
lutetium-177
metastatic castrate-resistant prostate cancer
radioligand therapy
radiopharmaceutical
prostate-specific membrane antigen
Online AccessGet full text

Cover

More Information
Summary:The therapeutic efficacy of a Russian radiopharmaceutical 177 Lu-DOTA-PSMA was studied in vivo using male BALB/c nu/nu (nude) mice with prostate carcinoma 22Rv1 xenografts by tumor growth inhibition criterion. The mean tumor volumes in mice treated with 177 Lu-DOTA-PSMA were significantly lower than in animals of the control group. There were no significant differences in the values of tumor growth inhibition between the groups of animals receiving 3.7 or 7.4 MBq of 177 Lu-DOTA-PSMA.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0007-4888
1573-8221
DOI:10.1007/s10517-024-05999-z